Non-Alcoholic Steatohepatitis Nash Market is expected to grow with a CAGR of 24.18% from 2024 to 2032

IMARC Group’s report titled “Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), Sales Channel (Hospital Pharmacy, Online Providers, Retail Pharmacy), End User (Hospitals, Clinics, Homecare Settings), and Region 2024–2032”. The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024–2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample

Factors Affecting the Growth of the Non-Alcoholic Steatohepatitis Industry:

• Rising Obesity Rates:

Obesity is closely linked to the development of NASH. The accumulation of excess fat in the liver, which is common in obese individuals, can lead to the progression of liver disease to NASH. Consequently, healthcare providers and patients are increasingly focused on addressing NASH, creating a growing market for diagnostic tests, treatments, and therapies. Obese individuals with NASH often require specialized medical attention and treatment. As more people are becoming obese and subsequently develop NASH, there is a greater need for healthcare providers to offer effective treatments, medications, and interventions. This is catalyzing the demand for pharmaceuticals and medical procedures associated with NASH management.

• Awareness and Diagnosis:

The increasing awareness about NASH is leading to a greater emphasis on early detection and diagnosis. As more individuals and healthcare professionals are recognizing the signs and risk factors of NASH, there is a higher likelihood of identifying the condition at an earlier stage. This is driving the demand for diagnostic tools and tests specific to NASH, including imaging techniques and blood markers. With improved awareness, the reported incidence of NASH is rising. Healthcare providers are better equipped to diagnose NASH, leading to more cases being documented. This increase in diagnosed cases boosts the overall demand for NASH-related healthcare services, medications, and interventions.

• Aging Population:

NASH is more commonly diagnosed in older adults. As the global population is aging, there is a natural increase in the number of individuals who are at a higher risk of developing NASH. This demographic shift leads to a growing pool of potential NASH patients, contributing to the growth of the market. Older adults often have comorbidities, such as diabetes, hypertension, and hyperlipidemia, which are known risk factors for NASH. The presence of these conditions in the aging population increases the likelihood of NASH development, leading to greater demand for NASH-related healthcare services and treatments.

Leading Companies Operating in the Global Non-Alcoholic Steatohepatitis Industry:

• Algernon Pharmaceuticals
• Galmed Pharmaceuticals Ltd
• Intercept Pharmaceuticals Inc.
• Zydus Lifesciences Limited

Non-Alcoholic Steatohepatitis Market Report Segmentation:

By Drug Type:

• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib
• Cenicriviroc
• Others

Vitamin E and pioglitazone represented the largest segment due to their effectiveness in managing NASH-related symptoms and complications, as well as their widespread availability and physician recommendations.

By Disease Cause:

• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity

Obesity accounted for the largest market share as it is a primary risk factor for NASH, and the increasing global prevalence of obesity is driving the demand for NASH-related products and services.

By Sales Channel:

• Hospital Pharmacy
• Online Providers
• Retail Pharmacy

Retail pharmacy exhibits a clear dominance in the market driven by its accessibility and convenience for patients seeking over the counter (OTC) medications and supplements commonly used in NASH management.

By End User:

• Hospitals
• Clinics
• Homecare Settings

Clinics hold the biggest market share, which can be attributed to essential healthcare facilities served by clinics for NASH diagnosis, treatment, and ongoing patient management, attracting a substantial patient population.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the non-alcoholic steatohepatitis market on account of the high prevalence of NASH and advanced healthcare infrastructure.

Global Non-Alcoholic Steatohepatitis Market Trends:

There is a growing emphasis on the development of accurate and non-invasive diagnostic tools for NASH. Innovations in imaging techniques, blood biomarkers, and liver fibrosis assessment methods are improving early detection rates.

Pharmaceutical companies are actively researching and developing new therapies and medications for NASH.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1–631–791–1145 | United Kingdom: +44–753–713–2163